Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer
Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs
Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer
Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy
Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC